Drugs / Hunterase
Trials 3 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 21 trial | ||||||
| Phase 2 | NCT02663024 | Dec 2016 → Dec 2019 | mucopolysaccharidosis type 2 | Green Cross Corporation | Unknown | No outcome recorded |
| Phase 32 trials | ||||||
| Phase 3 | NCT07344376 | May 2018 → Dec 2022 | mucopolysaccharidosis type 2 | GC Biopharma Corp | Completed | No outcome recorded |
| Phase 3 | NCT01645189 | Jul 2012 → Sep 2013 | — | Green Cross Corporation | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Hunterase | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01645189 ↗ |
| Known as | idursulfase-beta | “Hunterase(Idursulfase-beta) in Hunter Syndrome Patients” NCT01645189 ↗ |
| Modality | Protein / enzyme biologic | “Idursulfase Enzyme Replacement Therapy” NCT01645189 ↗ |
| Route | Intravenous | “administered by intravenous(IV) infusion” NCT01645189 ↗ |